Aligos Therapeutics (ALGS) Q4 2025 earnings review
Pipeline Advances, But the Cash Clock is Ticking
Aligos Therapeutics delivered a standard pre-revenue biotech quarter, marked by steady clinical progress overshadowed by an accelerating cash burn. The net loss of $19.9M looks vastly better than the $82.2M loss a year ago, but this is pure noise driven by non-cash warrant valuations. Looking at the core business, operating losses remain elevated as Phase 2 HBV trials progress. The real story is the strategic pivot of ALG-055009 toward an obesity combination therapy to attract a partner, and a shrinking cash runway that only extends into Q3 2026. Aligos needs a non-dilutive partnership—soon—to avoid raising capital under pressure.
🐂 Bull Case
The Phase 2 B-SUPREME study for pevifoscorvir sodium successfully completed planned enrollment for the HBeAg- cohort. Reaching this milestone keeps the company on track for crucial interim readouts in H1 and H2 2026.
Preclinical data showing synergistic weight loss when combining ALG-055009 with GLP-1s (tirzepatide/semaglutide) dramatically expands the drug's commercial appeal beyond MASH, potentially accelerating partnership discussions.
🐻 Bear Case
With $77.8M in cash and a burn rate of ~$21M per quarter, the runway guided to Q3 2026 means the company will likely need to raise funds or secure a partnership within the next 6-9 months to maintain leverage.
Management continues to 'evaluate options to fund continued development' for ALG-055009. Until a partner is secured, this promising asset is functionally stalled, yielding no clinical progress.
⚖️ Verdict: ⚪
Neutral. Aligos is hitting its clinical milestones, but the fundamental biotech tension remains: strong science fighting against a ticking financial clock. The pivot to positioning ALG-055009 for obesity is a smart commercial move, but execution on a partnership deal is now mandatory.
Key Themes
ALG-055009 Pivots to Obesity Combination Therapy
Aligos is aggressively repositioning its THR-β agonist (ALG-055009) from a pure MASH play to an obesity combination therapy. New in vivo data showed combining it with semaglutide increased maximum body weight loss from 23.9% (mono) to 33.0%. Combining it with high-dose tirzepatide pushed weight loss to ~40%. Crucially, the extra weight loss came from fat mass, sparing lean mass. This data is the bait management is using to secure a lucrative out-licensing deal.
Cash Runway Dependency
The balance sheet is stable but declining. Cash and investments dropped from $99.1M in Q3 2025 to $77.8M in Q4. While management reiterates funding into Q3 2026, biotech companies typically need to raise capital when they have 12 months of runway remaining. If a partnership for ALG-055009 is not announced soon, investors should brace for highly dilutive equity offerings before the 2026 HBV data readouts.
Pevifoscorvir Sodium (HBV) Remains on Track
The Phase 2 B-SUPREME study is successfully moving forward. The HBeAg- cohort (60 participants) completed enrollment in January 2026. The drug aims to hit three pillars of HBV pathogenesis (replication, integration, and viral reservoir maintenance). Execution here has been stable, setting up major catalyst events in 2026.
Amoytop Partnership Yields IND Progression
ALG-170675, a dual-mechanism antisense oligonucleotide (ASO) for HBV, was selected to proceed into IND-enabling studies. The key benefit here is capital efficiency: Aligos' partner, Amoytop, is funding the current development costs in China. This allows Aligos to advance a next-generation asset without draining its own limited cash reserves.
R&D Expense Normalization
After spiking to $23.9M in Q3 2025 due to the launch and heavy screening phase of the Phase 2 B-SUPREME trial, R&D expenses decelerated back down to $17.0M in Q4. While this preserves cash, investors must monitor if this lower run rate is sustainable as the HBeAg+ cohort continues to enroll.
Other KPIs
Stable. The operating loss remains the best indicator of core cash burn, stripping out the volatile non-cash warrant swings. This metric has remained tightly bound between $18.6M and $28.4M throughout 2025, landing at $21.8M in Q4. General & Administrative expenses are highly controlled, actually dropping YoY from $5.2M to $4.9M.
Reversing. The company recognized $60.2M in non-cash income for FY25 related to 2023 common warrants, a massive reversal from the $46.1M loss recorded in FY24. This accounting anomaly is the sole reason the full-year net loss artificially shrank to just $24.2M versus $131.2M in the prior year. Investors should entirely ignore net income metrics and focus on operating loss.
Guidance
Stable. Management maintained their timeline for cash exhaustion. With $77.8M in the bank, this implies an average expected burn rate of approximately $20-25M per quarter through mid-2026.
Stable. The first interim analysis will cover ~36 HBeAg- participants completing 12 weeks of treatment (enrollment threshold hit Q4 2025). The second analysis covers ~55 HBeAg+ participants at 24 weeks (enrollment threshold hit Jan 2026). These are the most critical binary events for the stock in the medium term.
Stable. Final data from the Phase 2 HBV study remains projected for 2027, well beyond the current cash runway. This structural misalignment forces the company to either raise capital on interim data or secure an external partnership beforehand.
Key Questions
Partnership Timeline for ALG-055009
With the new GLP-1 combination data in hand, what is a realistic timeline for securing an out-licensing deal, and what is the minimum upfront cash profile you are targeting to meaningfully extend the corporate runway?
Capital Raising Strategy
Given the cash runway ends in Q3 2026, do you plan to raise capital prior to the first interim readout of B-SUPREME in H1 2026, or are you confident you can wait until after the data is published?
Amoytop Financials
As ALG-170675 advances into IND-enabling studies funded by Amoytop, are there any near-term milestone payments tied to IND acceptance that will flow back to Aligos?